

## SUMMARY OF PRODUCT CHARACTERISTICS

### Attent 10 mg, 20 mg & 30 mg Tablets

#### 1. NAME OF THE MEDICINAL PRODUCT

Attent 10 mg  
Attent 20 mg  
Attent 30 mg

#### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

A single entity amphetamine product combining the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate.

<b>EACH TABLET CONTAINS</b>	<b>Attent 10 mg</b>	<b>Attent 20 mg</b>	<b>Attent 30 mg</b>
Dextroamphetamine Saccharate	2.5 mg	5 mg	7.5 mg
Amphetamine Aspartate Monohydrate	2.5 mg	5 mg	7.5 mg
Dextroamphetamine Sulfate	2.5 mg	5 mg	7.5 mg
Amphetamine Sulfate	2.5 mg	5 mg	7.5 mg
Total amphetamine base equivalence	6.3 mg	12.6 mg	18.8 mg

Excipients with known effect:

Saccharin sodium, compressible sugar, Attent 20 mg and 30 mg tablets contain FD & C Yellow No. 6 Aluminium lake (sunset yellow FCF). See section 4.4 "excipients with known effect".

For the full list of excipients, see section 6.1.

#### 3. PHARMACEUTICAL FORM

##### Tablets for oral administration.

##### ATTENT 10 mg:

Blue oval tablet, debossed with "b" over "972" between two horizontal lines on one side. On the other side, debossed with "1" and "0" on both sides of a bisect line [1 | 0] and between two horizontal lines.

##### ATTENT 20 mg:

Peach oval tablet, debossed with "b" over "973" between two horizontal lines on one side. On the other side, debossed with "2" and "0" on both sides of a bisect line [2 | 0] and between two horizontal lines.

##### ATTENT 30 mg

Peach oval tablet, debossed with "b" over "974" between two horizontal lines on one side. On the other side, debossed with "3" and "0" on both sides of a bisect line [3 | 0] and between two horizontal lines.

Attent tablets can be divided into equal parts.

AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.

MISUSE OF AMPHETAMINE MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.

#### **4. CLINICAL PARTICULARS**

##### **4.1 Therapeutic indications**

Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

##### **Attention Deficit Hyperactivity Disorder (ADHD)**

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition, known as DSM-IV and published by the American Psychiatric Association) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go;” excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

##### **Special Diagnostic Considerations:**

Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics.

##### **Need for Comprehensive Treatment Program:**

ATTENT tablets are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.

##### **Long-Term Use:**

The effectiveness of ATTENT tablets for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use ATTENT tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

## 4.2 Posology and method of administration

Regardless of indication, amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted according to the therapeutic needs and response of the patient. Late evening doses should be avoided because of the resulting insomnia.

### Attention Deficit Hyperactivity Disorder

Not recommended for children under 3 years of age

Children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.

### Narcolepsy

Usual dose 5 mg to 60 mg per day in divided doses, depending on the individual patient response.

Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

## 4.3 Contraindications

- Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, , glaucoma.
- Agitated states
- Patients with a history of drug abuse
- Known hypersensitivity or idiosyncrasy to amphetamines.
- In patients known to be hypersensitive to any of the active substances or to any of the excipients listed in section 6.1.  
Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products (see UNDESIRABLE EFFECTS).
- Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAIOs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crises (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE and INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).

## 4.4 Special warnings and precautions for use

### Serious Cardiovascular Events

## **Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems**

### Children and Adolescents

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.

Although some structural heart problems alone may carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug (see CONTRAINDICATIONS).

### Adults

Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see CONTRAINDICATIONS).

## **Hypertension and other Cardiovascular Conditions**

Stimulant medications cause a modest increase in average blood pressure (about 2 to 4 mmHg) and average heart rate (about 3 to 6 bpm) [see UNDESIRABLE EFFECTS], and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see CONTRAINDICATIONS).

## **Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications**

Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g. electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.

## **Psychiatric Adverse Events**

### **Pre-Existing Psychosis**

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder.

### **Bipolar Illness**

Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

## **Emergence of New Psychotic or Manic Symptoms**

Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

### **Aggression**

Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

### **Long-Term Suppression of Growth**

Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.

Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they will likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining weight as expected may need to have their treatment interrupted.

### **Seizures**

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.

### **Peripheral Vasculopathy, Including Raynaud's Phenomenon**

Stimulants, including ATTENT (Mixed Amphetamine Salts), used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

### **Serotonin Syndrome**

Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort [see Drug Interactions]. Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism [see CLINICAL PHARMACOLOGY]. The potential for a

pharmacokinetic interaction exists with the coadministration of CYP2D6 inhibitors which may increase the risk with increased exposure to ATTENT tablets. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 [see Drug Interactions].

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Concomitant use of ATTENT tablets with MAOI drugs is contraindicated [see Contraindications].

Discontinue treatment with dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of ATTENT tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate ATTENT tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.

### **Visual Disturbance**

Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

### **Other Precautions**

#### **General**

The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. ATTENT tablets should be used with caution in patients who use other sympathomimetic drugs.

#### **Tics**

Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications.

### **Information for Patients**

Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with amphetamine or dextroamphetamine and should counsel them in its appropriate use.

### **Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud's Phenomenon]**

Instruct patients beginning treatment with ATTENT about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.

Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.

**Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking ATTENT**

Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

### **Drug Abuse and Dependence**

Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

### **Excipients with Known Effect**

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodium-free".

This medicine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Attent 20 mg and 30 mg tablets contain FD & C Yellow No. 6 Aluminium lake that may cause allergic reactions.

## **4.5 Interaction with other medicinal products and other forms of interaction**

### *Acidifying Agents*

Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e.g. guanethidine, reserpine, glutamic acid HCl, ascorbic acid.) and urinary acidifying agents (ammonium chloride, sodium acid phosphate, methenamine salts).

### *Adrenergic Blockers*

Adrenergic blockers are inhibited by amphetamines.

### *Alkalinizing Agents*

Increase blood levels and potentiate the action of amphetamine. Co-administration of ATTENT tablets and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g. sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides)..

### *Tricyclic Antidepressants*

Amphetamines may enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. Monitor frequently and adjust or use alternative therapy based on clinical response. Examples of tricyclic antidepressants include desipramine, protryptiline.

### *CYP2D6 Inhibitors*

The concomitant use of ATTENT tablets and CYP2D6 inhibitors may increase the exposure of ATTENT tablets compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during ATTENT tablets initiation and after a dosage increase. If serotonin syndrome occurs, discontinue ATTENT tablets and the CYP2D6 inhibitor [see WARNINGS, OVERDOSAGE]. Examples of CYP2D6 Inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir.

*Serotonergic Drugs*

The concomitant use of ATTENT tablets and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during ATTENT tablets initiation or dosage increase. If serotonin syndrome occurs, discontinue ATTENT tablets and the concomitant serotonergic drug(s) [see WARNINGS and PRECAUTIONS]. Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort.

*MAO Inhibitors*

Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema and renal failure. Do not administer ATTENT tablets concomitantly or within 14 days after discontinuation MAOI (see Contraindications and Warnings). Examples of MAOIs include selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue.

*Antihistamines*

Amphetamines may counteract the sedative effect of antihistamines.

*Antihypertensives*

Amphetamines may antagonize the hypotensive effects of antihypertensives.

*Chlorpromazine*

Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.

*Ethosuximide*

Amphetamines may delay intestinal absorption of ethosuximide.

*Haloperidol*

Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.

*Lithium Carbonate*

The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.

*Meperidine (Pethidine)*

Amphetamines potentiate the analgesic effect of meperidine.

*Methenamine Therapy*

Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

*Norepinephrine*

Amphetamines enhance the adrenergic effect of norepinephrine.

*Phenobarbital*

Amphetamine may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.

*Phenytoin*

Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.

*Propoxyphene*

In cases of propoxyphene overdose, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

#### *Proton Pump Inhibitors (PPIs)*

Time to maximum concentration ( $T_{max}$ ) of amphetamine is decreased compared to when administered alone. Monitor patients for changes in clinical effect and adjust therapy based on clinical response. An example of proton pump inhibitor is omeprazole.

#### *Veratrum Alkaloids*

Amphetamines inhibit the hypotensive effect of veratrum alkaloids.

### **Drug/ Laboratory Test Interactions**

Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.

## **4.6 Fertility, pregnancy and lactation**

### **Fertility**

Amphetamine, in the enantiomer ratio present in ATTENT tablets (d- to l- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis).

### **Pregnancy**

Amphetamine, in the enantiomer ratio present in this product (d- to l- ratio of 3:1), had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and 8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<sup>2</sup> body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times that of a human dose of 30 mg/day [child] on a mg/m<sup>2</sup> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.

A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,l-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.

There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### ***Nonteratogenic Effects***

Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.

### **Lactation**

Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.

### **Pediatric Use**

Long-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age with Attention Deficit Hyperactivity Disorder.

### **Geriatric Use**

ATTENT tablets have not been studied in the geriatric population.

### **4.7 Effects on ability to drive and use machines**

This product may affect your or your child's ability to drive or do other dangerous activities.

### **4.8 Undesirable effects**

#### ***Cardiovascular***

Palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

#### ***Central Nervous System***

Psychotic episodes at recommended doses, overstimulation, restlessness, irritability, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, aggression, anger, logorrhea, dermatillomania,, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, seizures, stroke.

#### ***Eye Disorders***

Vision blurred, mydriasis.

#### ***Gastrointestinal***

Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.

#### ***Allergic***

Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported.

#### ***Endocrine***

Impotence, changes in libido, frequent or prolonged erections

#### ***Skin***

Alopecia

#### ***Musculoskeletal***

Rhabdomyolysis

#### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form:  
<https://sideeffects.health.gov.il>

### **4.9 Overdose Symptoms**

Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis.

Fatigue and depression usually follow the central nervous system stimulation. Serotonin syndrome has also been reported.

Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse.

Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

### **Treatment**

abuse Consult with a certified poison control center for up to date guidance and advice.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Mixed Salts Amphetamines

ATC Code: N06BA01

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

### **5.2 Pharmacokinetic properties**

ATTENT (Amphetamine Mixed Salts) tablets contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following administration of a single dose 10 or 30 mg of the product to healthy volunteers under fasted conditions, peak plasma concentrations occurred approximately 3 hours post-dose for both d-amphetamine and l-amphetamine. The mean elimination half-life ( $t_{1/2}$ ) for d-amphetamine was shorter than the  $t_{1/2}$  of the l-isomer (9.77-11 hours vs. 11.5-13.8 hours). The PK parameters ( $C_{max}$ ,  $AUC_{0-inf}$ ) of d-and l-amphetamine increased approximately three-fold from 10 mg to 30 mg indicating dose-proportional pharmacokinetics.

The effect of food on the bioavailability of Amphetamine Mixed Salts tablets has not been studied.

#### *Metabolism and Excretion*

Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain  $\alpha$  or  $\beta$  carbons to form alpha-hydroxyamphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy- amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.

Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. *In vitro* experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of auto-inhibition and the lack of information on the concentration of these metabolites relative to *in vivo* concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes *in vivo* can be made.

With normal urine pHs approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30%-40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that effect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamine's metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased.

### 5.3 Preclinical safety data

#### *Carcinogenesis/Mutagenesis and Impairment of Fertility*

No evidence of carcinogenicity was found in studies in which d,l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day [child] on a mg/m<sup>2</sup> body surface area basis.

Amphetamine, in the enantiomer ratio present in this product (d- to l- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test *in vivo* and was negative when tested in the E. coli component of the Ames test *in vitro*. D, l-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the *in vitro* sister chromatid exchange and chromosomal aberration assays.

Amphetamine, in the enantiomer ratio present in this product(d- to l- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 5 times the maximum recommended human dose of 30 mg/day on a mg/m<sup>2</sup> body surface area basis).

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, microcrystalline cellulose and saccharin sodium.

Each tablets also contains	10 mg	20 mg	30 mg
FD&C Blue No. 1 Aluminium Lake	v	--	--

FD&C Yellow No. 6 Aluminium Lake (sunset yellow FCF)	--	v	v
Sodium content per tablet (approximate)	0.45 mg	0.45 mg	0.67 mg
Sucrose content per tablet (approximate)	98 mg	93 mg	140 mg

## 6.2 Special precautions for storage

Store below 25°C and protect from light.

The medicine can be used for up to 90 days after first opening of the bottle, but not after the expiry date.

## 6.3 Nature and contents of container

Each plastic bottle of 30 tablets contains a desiccant.

להלן הבהרה לגבי כמות הטבליות שניתן לנפק עבור התכשיר אטנט: בהתאם לתקנות הרוקחים (ניפוקם והעברתם של סמים), תשמ"ג-1983, 3 (א) (5) והתוספת לתקנה זו, ניתן לנפק במרשם רופא מתאים כמות תרופה שלא תעלה על 40 מ"ג (בסיס) אמפטמין ליום.

לפיכך, בהתייחס לכמות בסיס האמפטמין בטבליה, ניתן לנפק את סך הכמויות החודשיות המירביות של טבליות אטנט כמפורט להלן:

מספר טבליות מירבי בחודש	מספר טבליות מירבי ליממה	תכולת בסיס האמפטמין בטבליה	
180	6	6.3 מ"ג	אטנט 10 מ"ג
90	3	12.6 מ"ג	אטנט 20 מ"ג
60	2	18.8 מ"ג	אטנט 30 מ"ג

ניפוק כמות העולה על 40 מ"ג ועד 100 מ"ג בסיס אמפטמין ליממה, דורש טופס מיוחד.

כלומר, עד מספר הטבליות המפורט בטבלה בעמודה "מספר טבליות מירבי בחודש", אין צורך בטופס מיוחד, מעבר למרשם הסמים לתכשיר.

## 7. Manufacturer and License Holder

Teva Israel Ltd.,  
124 Dvora HaNevi'a St., Tel Aviv 6944020

## 8. REGISTRATION NUMBERS

Attent 10 mg registration No.: 154-13-34222

Attent 20 mg registration No.: 154-14-34224

Attent 30 mg registration No.: 154-15-34225

**This leaflet was revised in February 2022 according to Ministry of Health guidelines.**